ACQUISITIONS AND OTHER DIVESTITURES (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cardioxyl Pharmaceuticals, Inc. [Member]
Acquisition and other divestitures [Line Items]
Asset acquisition upfront payment	$ 200
Contingent and regulatory milestone payments	1,900
Upfront payment allocated to research and development expenses	167
Deferred tax assets related to asset acquisition	33
Flexus Biosciences, Inc. [Member]
Acquisition and other divestitures [Line Items]
Asset acquisition upfront payment	800
Contingent and regulatory milestone payments	450
Upfront payment allocated to research and development expenses	800
Deferred tax assets related to asset acquisition	14
iPierian, Inc. [Member]
Acquisition and other divestitures [Line Items]
Asset acquisition upfront payment		$ 175
Contingent and regulatory milestone payments		550
Upfront payment allocated to research and development expenses		148
Deferred tax assets related to asset acquisition		$ 27
Other divestitures [Member]
Acquisition and other divestitures [Line Items]
Proceeds from divestiture of business	121
Gain on other divestitures	136
Deferred gain on other divestitures	$ 40